© Drug Hunter Inc. 2018-2023
Home > BMS-986202
oral JH2-binding Tyk2 inhibitor
Ph. I in psoriasis complete
backup candidate to BMS-986165 for psoriasis
J. Med. Chem., Dec. 28, 2020
Bristol-Myers Squibb, Princeton, NJ
Bristol Myers Squibb (BMS) oral JH2-domain binding Tyk2 kinase inhibitor
Drug Hunter is commited to helping industry innovators make informed decisions. Premium members have access to our library of the latest stories in science, written by scientists.
Request a trial to access insights powering the pros in our industry.
Molecules of the Month
Molecule of the Year